Stephen Stefano heads up Novasep North American business and PatrickGlaser leads Novasep Synthesis division.
Pompey, France, May 3rd, 2010 – Novasep, a leading supplier of manufacturing solutions to the life sciences industries, announces today the appointments of two highly experienced managers in its drive to grow the group’s US presence and develop its Novasep Synthesis division. Stephen F. Stefano becomes President & CEO of Novasep North American business, and Patrick A. Glaser President and CEO of the Novasep Synthesis division, a new position created as a result of its ongoing global integration. Stefano and Glaser also join Groupe Novasep’s executive management committee.
Before joining Novasep, Stefano was Senior Vice President at GlaxoSmithKline Pharmaceuticals in charge of Business Development for North America and New Product Planning. Stefano’s career spanned 29 years from 1981-2010 at Glaxo, GlaxoWellcome and GlaxoSmithKline, where he directed the sales of most business segments including Primary Care, Specialty, Hospital, and Managed Healthcare. He had full P&L responsibility for several multi-billion dollar divisions.
Glaser held senior management, strategic marketing and strategic business development positions successively at Knoll pharmaceuticals (1986-1998), BASF Corporation (1998-2005) and Dr Reddy’s Laboratories (2005-2009), where he was Vice President of its active pharmaceutical ingredient business, and recently in charge of a strategic contract manufacturing acquisition and integration. Born in Austria, Patrick has spent 25 years in the USA, and masters both European and US business environments.
Novasep expects both to play an important role in its development plans over the next few years. The US will be a major source of growth for both Novasep Process and Novasep Synthesis divisions, while the group’s activity in synthetic molecule manufacture will remain globally its largest source of revenues. These appointments follow last year’s hiring of Antoine Baule as president of the Novasep Process division, and the subsequent acquisition of the biopharmaceutical CMO Henogen, key milestones in the group’s strong expansion in biopharmaceutical manufacturing.
“Both Steve and Patrick will bring added quality, strength and experience to Novasep management,” said Roger-Marc Nicoud, Novasep’s President and CEO. “Patrick, with his double European and US culture and his broad manufacturing and operational experience, will spearhead Novasep Synthesis’ drive for international success. The deep knowledge and wide connections of Steve within the pharmaceutical and biopharmaceutical industries will be of primary importance to help us establish key partnerships with our customers, and make strategic progress in the US.”
Novasep will attend BIO Chicago, booth 5434, BIO Process zone, 3-6 May.
Novasep develops, markets and operates innovative technologies providing life science industries with safe and cost-effective production of active molecules. The global manufacturing solutions offered by Novasep include process development services; purification equipment and systems; contract manufacturing services; and complex active molecules. They apply to:
Synthetic molecules, combining conventional chemistry with special technologies and know-howsuch as hazardous chemistry, asymmetric synthesis, HPAPI handling, low temperature chemistry, biocatalysis, process chromatography, etc.
Biomolecules, with single unit operations or complete upstream and downstream processes including fermentation and cell culture, innovative batch and continuous purification technologies
such as membrane processes, ion exchange, chromatography, crystallization and formulation. As user of its own technologies, Novasep understands its customers’ challenges and shares its
experience and know-how to provide the best solution with guaranteed performance. The applications of Novasep’s offering cover the pharmaceutical, biopharmaceutical, food,
functional ingredients and bio-industries markets. The company has six FDA inspected manufacturing plants in France, Germany and the Bahamas,
two biopharmaceutical production sites in Belgium, R&D and equipment manufacturing facilities in the USA, China and France, and an office in Japan. It employs approximately 1,300 people and had annual revenues of EUR 300 million in 2009. More than 2,000 systems designed and produced by Novasep are currently purifying active molecules throughout the world. The
company holds more than 200 different patents covering its technologies and processes.